Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte

  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités

2 results

  • Language : Français
  • Topics : Hematologic cancers
  • Active substance : tyrosine
Filter
Topic
  • Diagnostic and therapeutic techniques (2)
  • Plus ...
    • Diagnostic techniques and procedures (2)
    • Plus ...
      • Biology (laboratory tests) (2)
      • Cell and tissue pathology (1)
    • Drug therapy (1)
  • Diseases and conditions (2)
  • Plus ...
    • Blood and lymphatic diseases (2)
    • Plus ...
      • Hematologic cancers (2)
  • Population groups (1)
  • Plus ...
    • Geriatrics (1)
Content type
  • Drugs, devices and medical acts (2)
  • Plus ...
    • Health technology assessment (2)
Date
  • Last five years (1)
Manufacturer
  • industriels (1)
Language
  • Français (2)
Active substance
  • cytarabine (1)
  • nilotinib (1)
  • tyrosine (2)
 More filter Other Filter Icon
Search Export

Drugs, devices and medical acts - 2 results

  • Targeted next generation sequencing gene panel in the medical management of chronic lymphocytic leukemia Brief INAHTAhta

    Health technology assessment - Posted on 2/8/2024
    Download document
    Add to my selection

  • Assessment of BCR-ABL fusion gene testing or quantification using RT-PCR in the diagnosis and therapeutic follow-up of chronic myeloid leukaemias and acute lymphoblastic leukaemias - INAHTA Brief

    Health technology assessment - Posted on 13/11/2017
    Download document
    Add to my selection

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
WJWb5TrdBq7xB7x2